Press release

Renowned Genomicist and Former Illumina Executive Dr. Mostafa Ronaghi Joins 1health Board of Directors, Announcing Investment in the Company

Sponsored by Businesswire

1health, the leading Testing as a Service (TaaS) company, today announced it has appointed genomics luminary Dr. Mostafa Ronaghi to the board of directors. Dr. Ronaghi has invested in the company during a period of incredible growth for 1health. The board addition and investment bolster the company’s mission to make personalized health, wellness and diagnostic testing accessible to all.

Dr. Ronaghi brings decades of operational and scientific expertise to 1health, and has been a crucial figure in the world of genomic research. At 1health, Dr. Ronaghi’s primary focus will be in providing strategic counsel and scientific insights, ensuring the company can continue to lay a solid foundation for growth. Throughout his career, Dr. Ronaghi has been passionate about the acceleration of personalized healthcare through testing, and has coached more than 100 companies in the field.

“Dr. Ronaghi’s addition to 1health was a natural fit,” said 1health CEO Mehdi Maghsoodnia. “We have been in the same orbit for years, always admiring his decades of research and operations experience at world-class institutions like Stanford University and Illumina, on key topics like microbiomes and genomics. It’s no doubt that his background, network, and experience will be indispensable to 1health in our continued growth and mission to provide testing to all.”

Dr. Ronaghi was Illumina’s CTO and Senior Vice President for about 13 years. As Chief Technology Officer, Dr. Ronaghi was responsible for leading internal research and technology development and was a co-founder of Illumina accelerator and GRAIL. In addition, he has served on the board of directors and the scientific advisory board of several companies.

Dr. Ronaghi has also co-founded several additional ventures in genomics and life science data including Avantome, ParAllele Bioscience, NextBio, and Pyrosequencing. Prior to these ventures, Dr. Ronaghi was a principal investigator at Stanford University from 1999 until 2008 and focused on the development of novel tools for molecular diagnostic applications. He holds more than 30 (pending and issued) patents, and has authored more than 90 peer-reviewed publications in journals and books.

“I’m thrilled to join the 1health board in order to make testing accessible to all,” said Dr. Ronaghi. “It’s become increasingly clear that both testing and personalization are the future of healthcare—and 1health is merging these together to make patient-first, personalized care as accessible as possible. I can’t wait to bring my expertise in genomics to one of the most exciting ventures in the industry.”

1health’s TaaS empowers partners to easily deploy, manage, and personalize diagnostic, health and wellness testing at scale. The company pioneered the concept and are the first in the field of DNA testing with a simple self-administered COVID-19 saliva test that was authorized by the FDA under EUA early last year.

For more information about 1health and to learn if its Testing as a Service (TaaS) platform is appropriate for your institution or group, please visit

About 1health

1health is the pioneer in enabling Testing as a Service (TaaS), making diagnostic testing easy and accessible for everyone. Its platform powers engaging health applications for telehealth companies, hospital systems, corporations and government agencies, school systems, and consumer brands, allowing them to easily deploy, manage, and personalize testing at scale. 1health’s cloud-based architecture allows for seamless management and tracing of tests, providing distribution across the country for faster testing, and an easy-to-read dashboard with actionable next steps after testing. 1health keeps more than seven million people healthy and informed through its partners and direct-to-consumer brand, Vitagene, and supports compliance with applicable privacy and security requirements of its partners and their customers. To learn more, go to